A striking 25 percent of the global population carries the APOE4 gene variant, making this genetic marker one of the most prevalent risk factors for late-onset Alzheimer’s disease. Regional analysis reveals even higher frequencies in Sub-Saharan Africa at 37 percent and the Middle East at 28 percent, underscoring the global health significance of APOE4-related disease vulnerability.
APOE4 carriers experience 2-3 fold increased Alzheimer’s risk compared to individuals with other APOE variants, largely through excessive neuroinflammation. New research from USC has identified cytosolic phospholipase A2 (cPLA2) as the specific enzyme driving this harmful inflammatory cascade. The development of selective cPLA2 inhibitors represents a major breakthrough, offering a targeted intervention that could reduce disease burden across millions of at-risk individuals worldwide. This precision approach addresses the biological mechanisms underlying APOE4-associated neurodegeneration.
Read the full article on GMJ Newsroom.
Was this article helpful?
